{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:54:46Z","timestamp":1787003686421,"version":"build-2736575974"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-21-110"],"award-info":[{"award-number":["BCRF-21-110"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","award":["SAC110052"],"award-info":[{"award-number":["SAC110052"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taiho Pharmaceuticals"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA224065"],"award-info":[{"award-number":["U54 CA224065"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nellie B. Connally Breast Cancer Research Endowment"},{"name":"The University of Texas MD Anderson Cancer Center Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer"},{"name":"The University of Texas MD Anderson Breast Cancer Moonshot Program"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR003167"],"award-info":[{"award-number":["UL1TR003167"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Several alterations in fibroblast growth factor receptor (FGFR) genes have been found in breast cancer; however, they have not been well characterized as therapeutic targets. Futibatinib (TAS-120; Taiho) is a novel, selective, pan-FGFR inhibitor that inhibits FGFR1-4 at nanomolar concentrations. We sought to determine futibatinib\u2019s efficacy in breast cancer models. Nine breast cancer patient\u2013derived xenografts (PDXs) with various\n                    <jats:italic>FGFR1-4<\/jats:italic>\n                    alterations and expression levels were treated with futibatinib. Antitumor efficacy was evaluated by change in tumor volume and time to tumor doubling. Alterations indicating sensitization to futibatinib in vivo were further characterized in vitro\n                    <jats:italic>. FGFR<\/jats:italic>\n                    gene expression between patient tumors and matching PDXs was significantly correlated; however, overall PDXs had higher FGFR3-4 expression. Futibatinib inhibited tumor growth in 3 of 9 PDXs, with tumor stabilization in an\n                    <jats:italic>FGFR2<\/jats:italic>\n                    -amplified model and prolonged regression (&gt;\u2009110\u00a0days) in an FGFR2 Y375C mutant\/amplified model. FGFR2 overexpression and, to a greater extent, FGFR2 Y375C expression in MCF10A cells enhanced cell growth and sensitivity to futibatinib. Per institutional and public databases,\n                    <jats:italic>FGFR2<\/jats:italic>\n                    mutations and amplifications had a population frequency of 1.1%\u20132.6% and 1.5%\u20132.5%, respectively, in breast cancer patients.\n                    <jats:italic>FGFR2<\/jats:italic>\n                    alterations in breast cancer may represent infrequent but highly promising targets for futibatinib.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-46586-y","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T12:02:33Z","timestamp":1700308953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer"],"prefix":"10.1038","volume":"13","author":[{"given":"Turcin","family":"Saridogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argun","family":"Akcakanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt W.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkan","family":"Yuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce P.","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jin","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick K. S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"DiPeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon B.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rodon Ahnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil","family":"Damodaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"key":"46586_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten, T. et al. The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing. Clin. Cancer Res. 22, 259\u2013267. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3212 (2016).","journal-title":"Clin. Cancer Res."},{"key":"46586_CR2","unstructured":"U.S. Food and Drug Administration. Pemazyre (pemigatinib) NDA 213736 approval letter, 4\/17\/2020., <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2020\/213736Orig1s000ltr.pdf> (Accessed 21 December 2021)."},{"key":"46586_CR3","unstructured":"U.S. Food and Drug Administration. Truseltiq (infigratinib) NDA 214622 approval letter, 5\/28\/2021., <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/214622Orig1s000ltr.pdf> (Accessed 21 December 2021)."},{"key":"46586_CR4","unstructured":"U.S. Food and Drug Administration. Balversa (erdafinitib), NDA 212018 approval letter, 4\/12\/2019., <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/212018Orig1s000ltr.pdf> (Accessed 21 December 2021)."},{"key":"46586_CR5","unstructured":"U.S. Food and Drug Administration. Lytgobi (futibatinib), NDA 214801 corrected approval letter, 10\/5\/2022., <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2022\/214801Orig1s000Correctedltr.pdf> (Accessed 1 March 2023)."},{"key":"46586_CR6","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","volume":"70","author":"N Turner","year":"2010","unstructured":"Turner, N. et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70, 2085\u20132094. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3746 (2010).","journal-title":"Cancer Res."},{"key":"46586_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nrm3528","volume":"14","author":"R Goetz","year":"2013","unstructured":"Goetz, R. & Mohammadi, M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat. Rev. Mol. Cell Biol. 14, 166\u2013180. https:\/\/doi.org\/10.1038\/nrm3528 (2013).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"46586_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41523-019-0114-x","volume":"5","author":"KM Levine","year":"2019","unstructured":"Levine, K. M. et al. FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. NPJ. Breast Cancer 5, 19. https:\/\/doi.org\/10.1038\/s41523-019-0114-x (2019).","journal-title":"NPJ. Breast Cancer"},{"key":"46586_CR9","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1158\/1078-0432.CCR-20-3905","volume":"27","author":"A Servetto","year":"2021","unstructured":"Servetto, A. et al. Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ER(+) breast cancer. Clin. Cancer Res. 27, 4379\u20134396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3905 (2021).","journal-title":"Clin. Cancer Res."},{"key":"46586_CR10","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1038\/onc.2009.489","volume":"29","author":"N Turner","year":"2010","unstructured":"Turner, N. et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29, 2013\u20132023. https:\/\/doi.org\/10.1038\/onc.2009.489 (2010).","journal-title":"Oncogene"},{"key":"46586_CR11","doi-asserted-by":"publisher","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","volume":"80","author":"H Sootome","year":"2020","unstructured":"Sootome, H. et al. Futibatinib is a novel irreversible FGFR 1\u20134 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 80, 4986\u20134997. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-2568 (2020).","journal-title":"Cancer Res."},{"key":"46586_CR12","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.annonc.2020.06.018","volume":"31","author":"R Bahleda","year":"2020","unstructured":"Bahleda, R. et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann. Oncol. 31, 1405\u20131412. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.018 (2020).","journal-title":"Ann. Oncol."},{"key":"46586_CR13","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","volume":"12","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam, F. et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: A phase I dose-expansion study. Cancer Discov. 12, 402\u2013415. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0697 (2022).","journal-title":"Cancer Discov."},{"key":"46586_CR14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0697","author":"F Meric-Bernstam","year":"2021","unstructured":"Meric-Bernstam, F. et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: A phase I dose-expansion study. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0697 (2021).","journal-title":"Cancer Discov."},{"key":"46586_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal, L. et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N. Engl. J. Med. 388, 228\u2013239. https:\/\/doi.org\/10.1056\/NEJMoa2206834 (2023).","journal-title":"N. Engl. J. Med."},{"key":"46586_CR16","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1158\/1078-0432.CCR-17-0615","volume":"23","author":"KW Evans","year":"2017","unstructured":"Evans, K. W. et al. A Population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1\/2 wild-type tumors. Clin. Cancer Res. 23, 6468\u20136477. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0615 (2017).","journal-title":"Clin. Cancer Res."},{"key":"46586_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/1078-0432.CCR-21-1810","volume":"28","author":"M Sanchez-Guixe","year":"2022","unstructured":"Sanchez-Guixe, M. et al. High FGFR1-4 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer. Clin. Cancer Res. 28, 137\u2013149. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1810 (2022).","journal-title":"Clin. Cancer Res."},{"key":"46586_CR18","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mce.2006.04.021","volume":"254\u2013255","author":"N Pitteloud","year":"2006","unstructured":"Pitteloud, N. et al. Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes. Mol. Cell Endocrinol. 254\u2013255, 60\u201369. https:\/\/doi.org\/10.1016\/j.mce.2006.04.021 (2006).","journal-title":"Mol. Cell Endocrinol."},{"key":"46586_CR19","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1007\/s12010-012-0061-6","volume":"169","author":"B Rajith","year":"2013","unstructured":"Rajith, B. & George Priya Doss, C. Disease-causing mutation in extracellular and intracellular domain of FGFR1 protein: Computational approach. Appl. Biochem. Biotechnol. 169, 1659\u20131671. https:\/\/doi.org\/10.1007\/s12010-012-0061-6 (2013).","journal-title":"Appl. Biochem. Biotechnol."},{"key":"46586_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2018.01.021","volume":"33","author":"PK Ng","year":"2018","unstructured":"Ng, P. K. et al. Systematic functional annotation of somatic mutations in cancer. Cancer Cell 33, 450\u2013462. https:\/\/doi.org\/10.1016\/j.ccell.2018.01.021 (2018).","journal-title":"Cancer Cell"},{"key":"46586_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","volume":"173","author":"MH Bailey","year":"2018","unstructured":"Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371\u2013385. https:\/\/doi.org\/10.1016\/j.cell.2018.02.060 (2018).","journal-title":"Cell"},{"key":"46586_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095 (2012).","journal-title":"Cancer Discov."},{"key":"46586_CR23","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088 (2013).","journal-title":"Sci. Signal"},{"key":"46586_CR24","doi-asserted-by":"publisher","first-page":"LBA1519","DOI":"10.1200\/JCO.2016.34.18_suppl.LBA1519","volume":"34","author":"N Wagle","year":"2016","unstructured":"Wagle, N. et al. The metastatic breast cancer project: A national direct-to-patient initiative to accelerate genomics research. J. Clin. Oncol. 34, LBA1519. https:\/\/doi.org\/10.1200\/JCO.2016.34.18_suppl.LBA1519 (2016).","journal-title":"J. Clin. Oncol."},{"key":"46586_CR25","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013713. https:\/\/doi.org\/10.1038\/nm.4333 (2017).","journal-title":"Nat. Med."},{"key":"46586_CR26","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: The catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947. https:\/\/doi.org\/10.1093\/nar\/gky1015 (2019).","journal-title":"Nucleic Acids Res."},{"key":"46586_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2174\/1568009618666171214114706","volume":"18","author":"A Sahores","year":"2018","unstructured":"Sahores, A. et al. Targeting FGFR with BGJ398 in breast cancer: effect on tumor growth and metastasis. Curr. Cancer Drug. Targets 18, 979\u2013987. https:\/\/doi.org\/10.2174\/1568009618666171214114706 (2018).","journal-title":"Curr. Cancer Drug. Targets"},{"key":"46586_CR28","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1158\/1535-7163.MCT-16-0518","volume":"16","author":"JD Karkera","year":"2017","unstructured":"Karkera, J. D. et al. Oncogenic characterization and pharmacologic sensitivity of activating fibroblast growth factor receptor (FGFR) genetic alterations to the selective FGFR inhibitor erdafitinib. Mol. Cancer Ther. 16, 1717\u20131726. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0518 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"46586_CR29","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","volume":"19","author":"F Andre","year":"2013","unstructured":"Andre, F. et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin. Cancer Res. 19, 3693\u20133702. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0190 (2013).","journal-title":"Clin. Cancer Res."},{"key":"46586_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s13402-020-00562-0","volume":"44","author":"TE Kahkonen","year":"2021","unstructured":"Kahkonen, T. E. et al. Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures. Cell Oncol. (Dordr) 44, 205\u2013218. https:\/\/doi.org\/10.1007\/s13402-020-00562-0 (2021).","journal-title":"Cell Oncol. (Dordr)"},{"key":"46586_CR31","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1245\/s10434-013-3456-x","volume":"21","author":"HJ Lee","year":"2014","unstructured":"Lee, H. J. et al. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. Ann. Surg. Oncol. 21, 1561\u20131568. https:\/\/doi.org\/10.1245\/s10434-013-3456-x (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"46586_CR32","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41467-019-09068-2","volume":"10","author":"L Formisano","year":"2019","unstructured":"Formisano, L. et al. Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer. Nat. Commun. 10, 1373. https:\/\/doi.org\/10.1038\/s41467-019-09068-2 (2019).","journal-title":"Nat. Commun."},{"key":"46586_CR33","doi-asserted-by":"publisher","first-page":"175883592091530","DOI":"10.1177\/1758835920915305","volume":"12","author":"N Xie","year":"2020","unstructured":"Xie, N. et al. FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients. Ther. Adv. Med. Oncol. 12, 1758835920915305. https:\/\/doi.org\/10.1177\/1758835920915305 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"46586_CR34","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1158\/1078-0432.CCR-19-3958","volume":"26","author":"P Mao","year":"2020","unstructured":"Mao, P. et al. Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER(+) metastatic breast cancer. Clin. Cancer Res. 26, 5974\u20135989. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3958 (2020).","journal-title":"Clin. Cancer Res."},{"key":"46586_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s10549-020-05865-2","volume":"184","author":"R Erber","year":"2020","unstructured":"Erber, R. et al. Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. Breast Cancer Res. Treat. 184, 311\u2013324. https:\/\/doi.org\/10.1007\/s10549-020-05865-2 (2020).","journal-title":"Breast Cancer Res. Treat."},{"key":"46586_CR36","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.18632\/oncotarget.6563","volume":"7","author":"YJ Shi","year":"2016","unstructured":"Shi, Y. J. et al. FGFR1 is an adverse outcome indicator for luminal a breast cancers. Oncotarget 7, 5063\u20135073. https:\/\/doi.org\/10.18632\/oncotarget.6563 (2016).","journal-title":"Oncotarget"},{"key":"46586_CR37","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4103\/IJPM.IJPM_87_20","volume":"64","author":"B Amina","year":"2021","unstructured":"Amina, B. et al. Fibroblast growth factor receptor 1 protein (FGFR1) as potential prognostic and predictive marker in patients with luminal B breast cancers overexpressing human epidermal receptor 2 protein (HER2). Indian J. Pathol. Microbiol. 64, 254\u2013260. https:\/\/doi.org\/10.4103\/IJPM.IJPM_87_20 (2021).","journal-title":"Indian J. Pathol. Microbiol."},{"key":"46586_CR38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/cas.12897","volume":"107","author":"M Tomiguchi","year":"2016","unstructured":"Tomiguchi, M. et al. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive\/human epidermal growth factor receptor-2-negative primary breast cancer. Cancer Sci. 107, 491\u2013498. https:\/\/doi.org\/10.1111\/cas.12897 (2016).","journal-title":"Cancer Sci."},{"key":"46586_CR39","doi-asserted-by":"publisher","first-page":"7950","DOI":"10.1038\/s41598-020-64534-y","volume":"10","author":"DL Cunningham","year":"2020","unstructured":"Cunningham, D. L. et al. Differential responses to kinase inhibition in FGFR2-addicted triple negative breast cancer cells: A quantitative phosphoproteomics study. Sci. Rep. 10, 7950. https:\/\/doi.org\/10.1038\/s41598-020-64534-y (2020).","journal-title":"Sci. Rep."},{"key":"46586_CR40","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1158\/0008-5472.CAN-09-4479","volume":"70","author":"JH Dey","year":"2010","unstructured":"Dey, J. H. et al. Targeting fibroblast growth factor receptors blocks PI3K\/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res. 70, 4151\u20134162. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-4479 (2010).","journal-title":"Cancer Res."},{"key":"46586_CR41","doi-asserted-by":"publisher","first-page":"8726","DOI":"10.1038\/s41598-019-45278-w","volume":"9","author":"J Kang","year":"2019","unstructured":"Kang, J. et al. A Selective FGFR inhibitor AZD4547 suppresses RANKL\/M-CSF\/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment. Sci. Rep. 9, 8726. https:\/\/doi.org\/10.1038\/s41598-019-45278-w (2019).","journal-title":"Sci. Rep."},{"key":"46586_CR42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13058-017-0807-8","volume":"19","author":"A Musolino","year":"2017","unstructured":"Musolino, A. et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(-) breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res. 19, 18. https:\/\/doi.org\/10.1186\/s13058-017-0807-8 (2017).","journal-title":"Breast Cancer Res."},{"key":"46586_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/1078-0432.CCR-19-1164","volume":"26","author":"R Hui","year":"2020","unstructured":"Hui, R. et al. Lucitanib for the treatment of HR(+)\/HER2(-) metastatic breast cancer: Results from the multicohort phase ii finesse study. Clin. Cancer Res. 26, 354\u2013363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1164 (2020).","journal-title":"Clin. Cancer Res."},{"key":"46586_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13058-019-1152-x","volume":"21","author":"M Quintela-Fandino","year":"2019","unstructured":"Quintela-Fandino, M. et al. Nintedanib plus letrozole in early breast cancer: A phase 0\/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition. Breast Cancer Res. 21, 69. https:\/\/doi.org\/10.1186\/s13058-019-1152-x (2019).","journal-title":"Breast Cancer Res."},{"key":"46586_CR45","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1200\/JCO.19.02630","volume":"38","author":"YK Chae","year":"2020","unstructured":"Chae, Y. K. et al. Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR Pathway: Results from the NCI-MATCH Trial (EAY131) subprotocol W. J. Clin. Oncol. 38, 2407\u20132417. https:\/\/doi.org\/10.1200\/JCO.19.02630 (2020).","journal-title":"J. Clin. Oncol."},{"key":"46586_CR46","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1158\/2159-8290.CD-15-1246","volume":"6","author":"A Pearson","year":"2016","unstructured":"Pearson, A. et al. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer Discov. 6, 838\u2013851. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1246 (2016).","journal-title":"Cancer Discov."},{"key":"46586_CR47","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/ijc.32224","volume":"145","author":"S Grunewald","year":"2019","unstructured":"Grunewald, S. et al. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int. J. Cancer 145, 1346\u20131357. https:\/\/doi.org\/10.1002\/ijc.32224 (2019).","journal-title":"Int. J. Cancer"},{"key":"46586_CR48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1810","author":"M Sanchez-Guixe","year":"2021","unstructured":"Sanchez-Guixe, M. et al. High FGFR1-4 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer. Clin. Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1810 (2021).","journal-title":"Clin. Cancer Res."},{"key":"46586_CR49","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1136\/bmj.296.6635.1491","volume":"296","author":"JJ Beutler","year":"1988","unstructured":"Beutler, J. J. et al. Paranormal healing and hypertension. Br. Med. J. (Clin. Res. Ed.) 296, 1491\u20131494. https:\/\/doi.org\/10.1136\/bmj.296.6635.1491 (1988).","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"46586_CR50","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1128\/mcb.7.12.4549-4552.1987","volume":"7","author":"Y Sugimoto","year":"1987","unstructured":"Sugimoto, Y., Roninson, I. B. & Tsuruo, T. Decreased expression of the amplified mdr1 gene in revertants of multidrug-resistant human myelogenous leukemia K562 occurs without loss of amplified DNA. Mol. Cell Biol. 7, 4549\u20134552. https:\/\/doi.org\/10.1128\/mcb.7.12.4549-4552.1987 (1987).","journal-title":"Mol. Cell Biol."},{"key":"46586_CR51","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1097\/SCS.0b013e3181ef2bab","volume":"21","author":"D Sureka","year":"2010","unstructured":"Sureka, D. & Hudgins, L. Fibroblast growth factor receptor 2 and its role in caudal appendage and craniosynostosis. J. Craniofac. Surg. 21, 1346\u20131349. https:\/\/doi.org\/10.1097\/SCS.0b013e3181ef2bab (2010).","journal-title":"J. Craniofac. Surg."},{"key":"46586_CR52","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ng0896-492","volume":"13","author":"KA Przylepa","year":"1996","unstructured":"Przylepa, K. A. et al. Fibroblast growth factor receptor 2 mutations in Beare\u2013Stevenson cutis gyrata syndrome. Nat. Genet. 13, 492\u2013494. https:\/\/doi.org\/10.1038\/ng0896-492 (1996).","journal-title":"Nat. Genet."},{"key":"46586_CR53","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/(SICI)1096-8628(19980401)76:4<362::AID-AJMG15>3.0.CO;2-M","volume":"76","author":"A Krepelova","year":"1998","unstructured":"Krepelova, A., Baxova, A., Calda, P., Plavka, R. & Kapras, J. FGFR2 gene mutation (Tyr375Cys) in a new case of Beare\u2013Stevenson syndrome. Am. J. Med. Genet. 76, 362\u2013364 (1998).","journal-title":"Am. J. Med. Genet."},{"key":"46586_CR54","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/01.mcd.0000194407.92676.9d","volume":"15","author":"J McGaughran","year":"2006","unstructured":"McGaughran, J. et al. A case of Beare\u2013Stevenson syndrome with a broad spectrum of features and a review of the FGFR2 Y375C mutation phenotype. Clin. Dysmorphol. 15, 89\u201393. https:\/\/doi.org\/10.1097\/01.mcd.0000194407.92676.9d (2006).","journal-title":"Clin. Dysmorphol."},{"key":"46586_CR55","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3892\/mmr_00000024","volume":"1","author":"RF Fonseca","year":"2008","unstructured":"Fonseca, R. F., Costa-Lima, M. A., Pereira, E. T., Castilla, E. E. & Orioli, I. M. Beare-Stevenson cutis gyrata syndrome: A new case of a c.1124Cright curved arrow G (Y375C) mutation in the FGFR2 gene. Mol. Med. Rep. 1, 753\u2013755. https:\/\/doi.org\/10.3892\/mmr_00000024 (2008).","journal-title":"Mol. Med. Rep."},{"key":"46586_CR56","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ebiom.2018.05.015","volume":"32","author":"ZY Hu","year":"2018","unstructured":"Hu, Z. Y. et al. Identifying circulating tumor DNA mutation profiles in metastatic breast cancer patients with multiline resistance. EBioMedicine 32, 111\u2013118. https:\/\/doi.org\/10.1016\/j.ebiom.2018.05.015 (2018).","journal-title":"EBioMedicine"},{"key":"46586_CR57","doi-asserted-by":"publisher","first-page":"7158","DOI":"10.1038\/sj.onc.1210529","volume":"26","author":"PM Pollock","year":"2007","unstructured":"Pollock, P. M. et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26, 7158\u20137162. https:\/\/doi.org\/10.1038\/sj.onc.1210529 (2007).","journal-title":"Oncogene"},{"key":"46586_CR58","doi-asserted-by":"publisher","first-page":"e60264","DOI":"10.1371\/journal.pone.0060264","volume":"8","author":"N Reintjes","year":"2013","unstructured":"Reintjes, N. et al. Activating somatic FGFR2 mutations in breast cancer. PLoS One 8, e60264. https:\/\/doi.org\/10.1371\/journal.pone.0060264 (2013).","journal-title":"PLoS One"},{"key":"46586_CR59","doi-asserted-by":"publisher","first-page":"e30801","DOI":"10.1371\/journal.pone.0030801","volume":"7","author":"SA Byron","year":"2012","unstructured":"Byron, S. A. et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One 7, e30801. https:\/\/doi.org\/10.1371\/journal.pone.0030801 (2012).","journal-title":"PLoS One"},{"key":"46586_CR60","doi-asserted-by":"publisher","first-page":"8713","DOI":"10.1073\/pnas.0803379105","volume":"105","author":"A Dutt","year":"2008","unstructured":"Dutt, A. et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. USA 105, 8713\u20138717. https:\/\/doi.org\/10.1073\/pnas.0803379105 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"46586_CR61","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","volume":"9","author":"L Goyal","year":"2019","unstructured":"Goyal, L. et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 9, 1064\u20131079. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0182 (2019).","journal-title":"Cancer Discov."},{"key":"46586_CR62","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","volume":"24","author":"S Pant","year":"2023","unstructured":"Pant, S. et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): An international, single-arm, phase 2 study. Lancet Oncol. 24, 925\u2013935. https:\/\/doi.org\/10.1016\/S1470-2045(23)00275-9 (2023).","journal-title":"Lancet Oncol."},{"key":"46586_CR63","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","volume":"13","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. et al. RLY-4008, the first highly selective FGFR2 Inhibitor with activity across FGFR2 alterations and resistance mutations. Cancer Discov. 13, 2012\u20132031. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0475 (2023).","journal-title":"Cancer Discov."},{"key":"46586_CR64","doi-asserted-by":"publisher","first-page":"e0136851","DOI":"10.1371\/journal.pone.0136851","volume":"10","author":"PF McAuliffe","year":"2015","unstructured":"McAuliffe, P. F. et al. Ability to generate patient-derived breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes. PLoS One 10, e0136851. https:\/\/doi.org\/10.1371\/journal.pone.0136851 (2015).","journal-title":"PLoS One"},{"key":"46586_CR65","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760. https:\/\/doi.org\/10.1093\/bioinformatics\/btp324 (2009).","journal-title":"Bioinformatics"},{"key":"46586_CR66","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491\u2013498. https:\/\/doi.org\/10.1038\/ng.806 (2011).","journal-title":"Nat. Genet."},{"key":"46586_CR67","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1373\/clinchem.2014.231100","volume":"61","author":"K Chen","year":"2015","unstructured":"Chen, K. et al. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin. Chem. 61, 544\u2013553. https:\/\/doi.org\/10.1373\/clinchem.2014.231100 (2015).","journal-title":"Clin. Chem."},{"key":"46586_CR68","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1593\/neo.111252","volume":"13","author":"RJ Lonigro","year":"2011","unstructured":"Lonigro, R. J. et al. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia 13, 1019\u20131025. https:\/\/doi.org\/10.1593\/neo.111252 (2011).","journal-title":"Neoplasia"},{"key":"46586_CR69","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/sj.bjc.6601894","volume":"91","author":"S Bamford","year":"2004","unstructured":"Bamford, S. et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91, 355\u2013358. https:\/\/doi.org\/10.1038\/sj.bjc.6601894 (2004).","journal-title":"Br. J. Cancer"},{"key":"46586_CR70","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1093\/bioinformatics\/btq330","volume":"26","author":"W McLaren","year":"2010","unstructured":"McLaren, W. et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26, 2069\u20132070. https:\/\/doi.org\/10.1093\/bioinformatics\/btq330 (2010).","journal-title":"Bioinformatics"},{"key":"46586_CR71","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic. Acids Res. 38, e164. https:\/\/doi.org\/10.1093\/nar\/gkq603 (2010).","journal-title":"Nucleic. Acids Res."},{"key":"46586_CR72","doi-asserted-by":"publisher","first-page":"e77945","DOI":"10.1371\/journal.pone.0077945","volume":"8","author":"Y Mao","year":"2013","unstructured":"Mao, Y. et al. CanDrA: Cancer-specific driver missense mutation annotation with optimized features. PLoS One 8, e77945. https:\/\/doi.org\/10.1371\/journal.pone.0077945 (2013).","journal-title":"PLoS One"},{"key":"46586_CR73","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-015-0155-1","volume":"7","author":"W Zhou","year":"2015","unstructured":"Zhou, W. et al. ClinSeK: A targeted variant characterization framework for clinical sequencing. Genome Med. 7, 34. https:\/\/doi.org\/10.1186\/s13073-015-0155-1 (2015).","journal-title":"Genome Med."},{"key":"46586_CR74","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46586-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T01:17:58Z","timestamp":1700356678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46586-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["46586"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-46586-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,18]]},"assertion":[{"value":"8 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TS, AA, MZ, KWE, EY, SS, BPK, XZ, MJH, HC, PKSN, and TD declare no competing interests.GBM served as a SAB\/consultant to AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, ImmunoMET, Infinity, Ionis, Lilly, Medacorp, Nanostring, PDX Pharmaceuticals, Signalchem Lifesciences, Tarveda, Turbine, Zentalis Pharmaceuticals. He has stock\/options\/financial in Catena Pharmaceuticals, ImmunoMet, SignalChem, Tarveda, and Turbine. He has licensed technologies as HRD assay to Myriad Genetics, DSP patents with Nanostring.JRA served in the advisory boards of Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceuticals\/Klus Pharma, Spectrum Pharmaceuticals, Inc., Pfizer, Roche Pharmaceuticals, Ellipses Pharma, Certera, Bayer, Molecular Partners, NovellusDX, IONCTURA SA, Kisoji Biotechnology, Inc. He received research funding\/clinical research (to institution) from Bayer, Novartis, Blueprint Medicines, Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAlta, Pfizer, GenMab, CytomX, Kelun-Biotech, Takeda-Millenium, GlaxoSmithKline, Ipsen. He received travel reimbursement from ESMO, Department of Defense, Merck Sharp & Dohme, Louisiana State University, Kelun Pharmaceuticals\/Klus Pharma, Huntsman Cancer Institute, Cancer Core Europe, Karolinska Cancer Institute, King Abdullah International Medical Research Center, Bayer, WIN Consortium, Janssen, Molecular Partners. He also received funding from the European Journal of Cancer, VHIO\/Ministero De Empleo Y Seguridad Social, Chinese University of Hong Kong, SOLTI, Elsevier, GlaxoSmithKline.SD received grant\/research support from Guardant Health, Taiho, EMD Serano, Novartis, CPRIT, SermonixHe served in the advisory committees of ASCO, ABIM.FM-B served as a consultant to AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, Daiichi Sankyo Co. Ltd., DebioPharm, Ecor1 Capital, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., GT Apeiron, Genentech Inc., Harbinger Health, IBM Watson, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, Lengo Therapeutics, Menarini Group, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Protai Bio Ltd, Samsung Bioepis, Seattle Genetics Inc., Tallac Therapeutics, Tyra Biosciences, Xencor, and Zymeworks. She served in the advisory committees of Black Diamond, Biovica, Eisai, FogPharma, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeutics, OnCusp Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Sanofi, Silverback Therapeutics, Spectrum Pharmaceuticals, and Zentalis. She has sponsored research (to the institution) from Aileron Therapeutics, Inc. AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical, Novartis, Puma Biotechnology Inc., and Taiho Pharmaceutical Co. She has honoraria with Chugai Biopharmaceuticals. She has other (travel related) support from European Organisation for Research and Treatment of Cancer (EORTC), and European Society for Medical Oncology (ESMO).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20223"}}